Plain-English translation of NCT03909412 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Multiple Myeloma research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing , a cancer-fighting medication, combined with two other drugs to help mobilize (move) stem cells from your bone marrow into your bloodstream so they can be collected. These collected stem cells will then be used in a transplant to help treat your multiple myeloma. The study will test three different doses of the medication to find the safest and most effective level.
Currently, doctors use standard methods to collect stem cells for transplants in myeloma patients, but researchers want to see if this medication combination can do the job more effectively and with fewer side effects.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive the study medication (along with and ) in an outpatient setting over a few hours. About a week later, you'll start daily injections to boost your white blood cells, and around day 12, you'll have your stem cells collected through a special catheter over several days. After successful collection, you will proceed to a standard stem cell transplant using melphalan, and then be monitored monthly to check how well the treatment is working.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States